News
The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
The analyst further reasoned that the high ocular toxicity rates, including keratopathy and visual acuity changes, are ...
The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback